Answers are grounded in this paper and cite their sources.
Premature ovarian failure (POF) is exhibiting a progressively younger onset age. Its etiology involves multiple factors, including genetics, immunity, mitochondrial dysfunction, iatrogenic causes, and environmental influences. This disease can lead to infertility, menstrual irregularities, hot flushes, and urogenital atrophy, severely compromising women’s reproductive health and quality of life. Given the limited available therapeutic options, there is an urgent need to explore novel treatment strategies. Exosomes derived from mesenchymal stem cells (MSC-exos) are a cell-free therapy for the treatment of POF, with low oncogenic risks and immunogenicity. Studies have confirmed that the MSC-exos ameliorate POF through multiple mechanisms, including regulating the proliferation and apoptosis of granulosa cells (GCs), activating follicular development, promoting angiogenesis, resisting oxidative stress, alleviating fibrosis, and inhibiting inflammation. This review systematically summarizes the etiology and pathological characteristics of POF, elaborates the specific mechanisms of the exosomes in POF, and explores exosomes optimization strategies based on preconditioning, surface functionalization, genetic engineering, tissue engineering, and exosome-based drug delivery. Finally, in light of the current state of the field, it critically discusses the limitations of MSC-exos in premature ovarian failure-related research and their application prospects. This narrative review provides valuable insights and novel research directions for the design of innovative therapeutic strategies against POF.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: